Understanding how the CB1 receptor signals in the body
Deciphering the complex pharmacology of CB1: towards the understanding of a third signaling pathway
This study is looking at how a specific receptor in our body, called the CB1 receptor, works with other proteins to help us understand pain better, with the hope of finding new ways to manage pain more effectively for people who need it.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10906264 on NIH RePORTER |
What this research studies
This research investigates the complex signaling pathways of the CB1 receptor, which is involved in various physiological processes. By exploring how this receptor interacts with different proteins and pathways, the study aims to uncover new mechanisms that could lead to better pain management and treatment options. The approach includes examining the role of specific proteins and their interactions in cell signaling, which may reveal novel therapeutic targets for analgesic drugs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic pain conditions who may benefit from enhanced analgesic therapies.
Not a fit: Patients who do not experience chronic pain or those who are not responsive to cannabinoid-based treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved pain relief treatments by targeting new signaling pathways associated with the CB1 receptor.
How similar studies have performed: Previous research has shown promising results in understanding GPCR signaling, suggesting that this approach could yield valuable insights into pain management.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Brailoiu, Eugen — Temple Univ of the Commonwealth
- Study coordinator: Brailoiu, Eugen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.